{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:08:23Z","timestamp":1776866903580,"version":"3.51.2"},"reference-count":136,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T00:00:00Z","timestamp":1460073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004426","name":"Atlantic Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000909","name":"John A. Hartford Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000909","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","award":["K23\u2010DK090303"],"award-info":[{"award-number":["K23\u2010DK090303"]}],"id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","award":["1R01DK106419\u201001"],"award-info":[{"award-number":["1R01DK106419\u201001"]}],"id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000384","name":"Higher Education Funding Council for England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non\u2010alcoholic fatty liver disease (NAFLD) can lead to non\u2010alcoholic steatohepatitis (<jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content>) and cirrhosis. Fibrosis predicts worse outcomes and mortality. New treatments targeting fibrosis are being investigated to reverse disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review the new pipeline therapeutic agents targeting fibrosis in <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients, with particular focus on clinical trials in which reversing fibrosis and portal hypertension are the primary outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The literature was searched in PubMed between January 2000 and January 2016 using search terms non\u2010alcoholic fatty liver disease and NASH, with filters of \u2018English language\u2019. We focused on fibrosis improvement as the key outcome. We also searched the ClinicalTrials.gov for promising agents that target fibrosis in <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant advances have been made on approaches targeting fibrosis in <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients. Many therapeutic agents are already in development, some of which have shown promising results in preclinical and phase I studies. Novel therapies have entered phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> studies targeting fibrosis reversal and\/or improvement in portal hypertension. Innovative studies have also started looking into combining these agents, aiming at different mechanisms to maximise therapeutic outcomes. We found five clinical trials in phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> and one in phase III focusing on fibrosis in <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients as key outcomes. One of the phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trials is using combination therapy to target fibrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ongoing research studies are already investigating new pathways aimed at reversing fibrosis in <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients. Novel therapeutic agents are in development and are expected to offer unique options to <jats:styled-content style=\"fixed-case\">NASH<\/jats:styled-content> patients with advanced fibrosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13620","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T18:00:57Z","timestamp":1460311257000},"page":"1109-1123","source":"Crossref","is-referenced-by-count":45,"title":["Review article: emerging anti\u2010fibrotic therapies in the treatment of non\u2010alcoholic steatohepatitis"],"prefix":"10.1111","volume":"43","author":[{"given":"M.","family":"Noureddin","sequence":"first","affiliation":[{"name":"Fatty Liver Program Division of Digestive and Liver Diseases Comprehensive Transplant Center Cedars\u2010Sinai Medical Center Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q. M.","family":"Anstee","sequence":"additional","affiliation":[{"name":"Liver Research Group Institute of Cellular Medicine The Medical School Newcastle University Newcastle\u2010upon\u2010Tyne UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Loomba","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of California, San Diego La Jolla CA USA"},{"name":"Division of Epidemiology University of California, San Diego La Jolla CA USA"},{"name":"NAFLD Research Center University of California, San Diego La Jolla CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,4,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.020"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204265"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.034"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.257"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23622"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2901"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5309"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562946"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00248"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.092144"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0002"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.205088"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23046"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00537.2004"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1663"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21867"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.052"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.022"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23599"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.038"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"Review Team","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"e_1_2_7_26_1","unstructured":"FriedmanSL.Pathogenesis of hepatic fibrosis. In: UpToDate PostTW(Ed) UpToDate Waltham MA. (Accessed on March 23 2016)."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(79)80170-5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004410051073"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02595.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2012.256"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10809"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26081"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25559"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25742"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306842"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.04.013"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2011.06.029"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00457-4"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2013.08.174"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.05.029"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20023"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.032"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26318"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05996.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.09.049"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26604"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.018"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.024"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.040"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-005-0200-2"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26491"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.033"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/362847"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22306"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.019"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32831bc3d6"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i13.1725"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23785"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61425-1"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25606"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.05.028"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27999"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04912.x"},{"key":"e_1_2_7_66_1","unstructured":"FriedmanSL.Emerging therapies for hepatic fibrosis: uptodate.com 2014."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25762"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.06.013"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0214"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28392"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198304283081703"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.014"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.042"},{"key":"e_1_2_7_75_1","first-page":"5","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali AH","year":"2015","journal-title":"Ann Transl Med"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049904b"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/934396"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3760"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25938"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24281"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24465"},{"key":"e_1_2_7_83_1","first-page":"192","article-title":"Pentoxifylline suppression of tumor necrosis factor gene transcription","volume":"110","author":"Doherty GM","year":"1991","journal-title":"Surgery"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9723-y"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31539-X"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505818200"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.3.657"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1103160"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1128294"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.10.039"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25778"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24544"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27999"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000719"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi201121m"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00794.x"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083481"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075361"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22952"},{"key":"e_1_2_7_100_1","first-page":"221A","article-title":"Anti\u2010fibrotic and anti\u2010inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH","volume":"58","author":"Lefebvre E","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_7_101_1","first-page":"1381A","article-title":"Significant anti\u2010fibrotic a'activity of cenicriviroc, a dual CCR2\/CCR5 antagonist, in a rat model of thioacetamide\u2010induced liver fibrosis and cirrhosis","volume":"58","author":"Hong F","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(94)34105-2"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1989.tb14913.x"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/aob\/mcf118"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2008.12.007"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200900119"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.520"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-1-200501040-00110"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1437"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201100093"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2010.08.003"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2009.28548"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0038-T"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23279"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24731"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.07.014"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12379"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22848"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1571276"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2010.10.002"},{"key":"e_1_2_7_122_1","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller R","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1887-4"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.068890"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.016"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23167"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24747"},{"key":"e_1_2_7_128_1","unstructured":"ShiffmanM FreilichB VuppalanchiR et al.A placebo\u2010controlled multicenter double\u2010blind randomised trial of emricasan (IDN\u20106556) in subjects with non\u2010alcoholic fatty liver disease (NAFLD) and raised transaminases. In: International Liver Congress 2015 the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) Vienna Austria April 22\u201026 2015."},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26461"},{"key":"e_1_2_7_130_1","first-page":"261A","article-title":"An international, phase 2 randomized controlled trial of the dual PPAR \u03b1\u2010\u03b4 agonist GFT505 in adult patients with NASH","volume":"62","author":"Ratziu V","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.038"},{"key":"e_1_2_7_132_1","unstructured":"KarnikS CharltonMR LiL et al.Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis. In: The Liver Meeting 2015 San Francisco CA November 13\u201317 American Association for the Study of Liver Diseases 2015."},{"key":"e_1_2_7_133_1","unstructured":"KarnikS CharltonM PopovY et al.Pharmacological inhibition of apoptosis signal\u2010regulating kinase 1 (ASK1) in a murine model of NASH with pre\u2010existing disease blocks fibrosis steatosis and insulin resistance. In: The Liver Meeting 2014 Boston Massachusetts November 7\u201311 American Association for the Study of Liver Diseases 2014."},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070599"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2014.07.003"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2208"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27720"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13620","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:25:41Z","timestamp":1695569141000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,8]]},"references-count":136,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/apt.13620"],"URL":"https:\/\/doi.org\/10.1111\/apt.13620","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,8]]}}}